Ambrisentantable Market

Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.

Ambrisentantable Market contains market size and forecasts of Ambrisentantable in global, including the following market information:

Global Ambrisentantable Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Ambrisentantable Market Sales, 2017-2022, 2023-2028, (M Pcs)

Global top five Ambrisentantable companies in 2021 (%)

The global Ambrisentantable market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

5 mg Tablet Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Ambrisentantable include GSK, Actavis (TEVA ), Gilead Sciences, Mylan Pharmaceuticals, Sigmapharm Laboratories, Noorik BioPharma, Cipla, Cadila Healthcare and Sun Pharmaceutical Industries, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Ambrisentantable manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Ambrisentantable Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Pcs)

Global Ambrisentantable Market Segment Percentages, by Type, 2021 (%)

5 mg Tablet

10 mg Tablet

Global Ambrisentantable Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Pcs)

Global Ambrisentantable Market Segment Percentages, by Application, 2021 (%)

Cirrhosis Of The Liver

High Blood Pressure

Hepatorenal Syndrome

Graft Function Is Delayed

Pulmonary Hypertension

Heart Failure

Chronic Renal Failure

Idiopathic Pulmonary Fibrosis

Other

Global Ambrisentantable Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Pcs)

Global Ambrisentantable Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Ambrisentantable revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Ambrisentantable revenues share in global market, 2021 (%)

Key companies Ambrisentantable sales in global market, 2017-2022 (Estimated), (M Pcs)

Key companies Ambrisentantable sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

GSK

Actavis (TEVA )

Gilead Sciences

Mylan Pharmaceuticals

Sigmapharm Laboratories

Noorik BioPharma

Cipla

Cadila Healthcare

Sun Pharmaceutical Industries

Hansoh Pharma

CTTQ

Zhejiang Haosen Pharmaceutical